title: Clinical resolution of vemurafenib-induced squamous cell carcinoma with topical 5-fluorouracil.
authors.affiliation: Department of Dermatology, Chelsea & Westminster Hospital NHS Foundation Trust, 369 Fulham Road, London, SW10 9NH, U.K. Rs280@doctors.org.uk.
authors.forename: R
authors.initials: R
authors.lastname: Sinha
authors.forename: J
authors.initials: J
authors.lastname: Larkin
authors.forename: L
authors.initials: L
authors.lastname: Fearfield
mesh_terms: D000279:Administration, Cutaneous; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000188:drug therapy; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006119:Groin; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008207:Lymphatic Metastasis; D008875:Middle Aged; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000188:drug therapy; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D005472:Fluorouracil